381 related articles for article (PubMed ID: 27538505)
1. Could patents interfere with the development of a cardiovascular polypill?
Beall RF; Schwalm JD; Huffman MD; McCready T; Yusuf S; Attaran A
J Transl Med; 2016 Aug; 14(1):242. PubMed ID: 27538505
[TBL] [Abstract][Full Text] [Related]
2. In which developing countries are patents on essential medicines being filed?
Beall RF; Blanchet R; Attaran A
Global Health; 2017 Jun; 13(1):38. PubMed ID: 28651631
[TBL] [Abstract][Full Text] [Related]
3. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
4. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
[TBL] [Abstract][Full Text] [Related]
5. The global intellectual property ecosystem for insulin and its public health implications: an observational study.
Kaplan WA; Beall RF
J Pharm Policy Pract; 2017; 10():3. PubMed ID: 27446593
[TBL] [Abstract][Full Text] [Related]
6. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
Matthews JH
Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
[TBL] [Abstract][Full Text] [Related]
7. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
8. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
Son KB; Lopert R; Gleeson D; Lee TJ
Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
[TBL] [Abstract][Full Text] [Related]
9. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
10. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
11. Mixed WTO ruling on generic drug development.
Elliott R
Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195
[TBL] [Abstract][Full Text] [Related]
12. Characteristics Of Key Patents Covering Recent FDA-Approved Drugs.
Van de Wiele VL; Torrance AW; Kesselheim AS
Health Aff (Millwood); 2022 Aug; 41(8):1117-1124. PubMed ID: 35914209
[TBL] [Abstract][Full Text] [Related]
13. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?
Beall RF; Nickerson JW; Kaplan WA; Attaran A
PLoS One; 2016; 11(2):e0148939. PubMed ID: 26910128
[TBL] [Abstract][Full Text] [Related]
14. Herbal drug patenting in India: IP potential.
Sahoo N; Manchikanti P; Dey SH
J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
[TBL] [Abstract][Full Text] [Related]
15. Global research on artemisinin and its derivatives: Perspectives from patents.
Liu K; Zuo H; Li G; Yu H; Hu Y
Pharmacol Res; 2020 Sep; 159():105048. PubMed ID: 32590098
[TBL] [Abstract][Full Text] [Related]
16. The Politics and Policies of Regulating Generics in Latin America: A Survey of Seventeen States.
Sweet CM
J Health Polit Policy Law; 2017 Jun; 42(3):485-512. PubMed ID: 28213391
[TBL] [Abstract][Full Text] [Related]
17. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.
Shin YS
Pharm Pat Anal; 2016 Jul; 5(4):237-48. PubMed ID: 27338849
[TBL] [Abstract][Full Text] [Related]
18. Development and Innovation on Dental Products in Argentina: A Technological Prospecting Based on Patents.
Valadas LAR; Oliveira Filho RD; Lotif MAL; Júnior FJG; Júnior EAD; Bandeira MAM; Squassi A
Recent Pat Biotechnol; 2021; 15(1):3-11. PubMed ID: 33305714
[TBL] [Abstract][Full Text] [Related]
19. Biological patent thickets and delayed access to biosimilars, an American problem.
Goode R; Chao B
J Law Biosci; 2022; 9(2):lsac022. PubMed ID: 36072417
[TBL] [Abstract][Full Text] [Related]
20. Patenting and patent challenges in South Korea after introducing a patent linkage system.
Son KB
Global Health; 2022 Nov; 18(1):95. PubMed ID: 36371241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
